Carcinoma

Researchers are testing whether giving adebrelimab, apatinib mesylate, and chemotherapy before surgery helps people with limited-stage small cell lung cancer. The study enrolls adults with early-stage disease that surgeons can remove. Participants receive the drug combination for…

Researchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …

The PURITY trial compares giving a three-drug chemotherapy combination before surgery with going straight to surgery in people with biliary tract cancer that can be removed but has a high risk of returning. Participants are adults under 75 with confirmed, non-metastatic biliary t…

This early-stage trial tests a personalized peptide vaccine for people with a rare liver cancer called fibrolamellar hepatocellular carcinoma (FLC) or other tumors that share a specific genetic change (DNAJB1-PRKACA fusion). The vaccine is designed to train the body's immune cell…

This study tests a new combination of two drugs (tulmimetostat and JSB462) in men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The trial has two parts: first, finding the safest dose, then comparing the combination to usual car…

This early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…

This pilot study tests a device that uses short, high-frequency electrical pulses to shrink or destroy soft tissue tumors in people with metastatic breast cancer. The trial will enroll 20 adults with tumors near the skin that are at least 1 cm but no larger than 5 cm. The main go…

This study tests whether a combination of drugs (pembrolizumab and N-803, with or without special immune cells called PD-L1 t-haNK cells) can help shrink head and neck cancers before surgery. About 40 adults with untreated, HPV-negative head and neck cancer will receive these tre…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before surgery helps shrink tumors in people with high-grade upper urinary tract cancer. About 131 adults will be randomly assigned to receive either chemo alone or chemo plus durvalumab be…

Researchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

This rollover study allows up to 40 people with KRAS G12C-mutated lung or other solid tumors who are already benefiting from opnurasib in a Novartis trial to keep receiving the drug. Participants continue their current dose of opnurasib alone or with TNO155 or trametinib. The goa…

This phase 2 trial tests whether two immunotherapy drugs, botensilimab and balstilimab, can clear tiny amounts of cancer DNA from the blood of people with stage II or III colorectal cancer who have completed standard treatment. The study enrolls 20 adults whose blood still shows …

This phase III trial is testing whether the immunotherapy drug atezolizumab, given after surgery, can prevent stage I non-small cell lung cancer from returning. About 336 patients who have had their tumor completely removed will be randomly assigned to receive either atezolizumab…

This phase II trial tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy, with or without additional hormone-blocking pills, can better control low-volume metastatic hormone-sensitive prostate cancer. The study enrolls men whose cancer has s…

This study tests a new drug combination (alisertib plus paclitaxel) in people with small cell lung cancer who have already tried other treatments. The main goal is to find safe doses and see what side effects occur. About 50 adults will take alisertib pills and receive paclitaxel…

This early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…

This study compares a new boost approach called irreversible electroporation (IRE) using the NanoKnife system against the standard radiation boost for men with intermediate-risk prostate cancer. All participants will receive standard stereotactic body radiation therapy (SBRT), bu…

This trial tests a two-part approach for advanced clear cell kidney cancer that has stopped responding to standard treatments. First, an imaging injection (PD-32766D) lights up cancer cells that have a specific marker (CA9). If the scan shows the marker is present, participants t…

This early-phase trial tests a new drug, GSK5458514, designed to help the immune system attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The study will first find a safe dos…

This phase 3 study compares two immunotherapy drugs—rilvegostomig and pembrolizumab (Keytruda)—each combined with standard chemotherapy, as a first treatment for people with advanced squamous non-small cell lung cancer that has a specific protein (PD-L1). About 880 participants w…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This phase 2 trial tests a drug called navlimetostat in about 130 people with advanced or metastatic non-small cell lung cancer that has a specific genetic change (MTAP deletion) and has worsened after other treatments. The main goal is to see if the drug can shrink tumors. Resea…

This phase 3 trial tests whether a personalized mRNA cancer vaccine (intismeran) alone or combined with an immunotherapy drug (pembrolizumab) can prevent non-small cell lung cancer from coming back after complete surgical removal. About 876 people with high-risk stage I lung canc…

This phase 2 trial is testing whether adjusting the dose of the drug belinostat based on a person's genetics can make treatment safer and more effective for high-grade neuroendocrine carcinoma. About 60 adults will receive belinostat along with two other chemotherapy drugs, cispl…

This study tests a drug called sacituzumab tirumotecan in 20 people with a rare and aggressive kidney cancer (SMARCB1-deficient renal medullary carcinoma) that has worsened after at least one prior treatment. The goal is to see if the drug can shrink or control the cancer. Resear…

This trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…

This phase 2 study tests an experimental drug called BT5528 in adults with metastatic pancreatic cancer that has spread and worsened after one prior treatment. The drug targets a specific protein on cancer cells. Researchers will measure how well it shrinks tumors and track side …

This early-stage trial is testing whether an oral probiotic called R-5780 is safe and tolerable when taken alongside a standard PD-1 checkpoint inhibitor in people with advanced solid tumors (like melanoma or certain skin cancers). About 33 adults whose cancer has not responded t…

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This large trial is testing whether a blood test that looks for tumor DNA can help decide who needs immunotherapy after surgery for muscle-invasive urothelial cancer. About 992 participants will be assigned to different treatment plans based on their blood test results. The goal …

This phase 3 trial tests whether adding targeted drugs (trastuzumab and pertuzumab) to standard chemotherapy can better shrink tumors in people with HER2-positive endometrial cancer. The study plans to enroll 360 participants with various stages of the disease. However, the trial…

This study compares two treatments for people with high-stage, estrogen-positive, HER2-negative breast cancer that has a low genetic risk of returning. One group gets standard hormone therapy plus a targeted pill (ribociclib), while the other gets chemotherapy first, then the sam…

This phase 2 trial is testing whether a combination of three drugs—nivolumab, ipilimumab, and cabozantinib—can help people with kidney cancer that has spread to the brain. The study will enroll 20 participants who have not had prior treatment for their brain metastases. The main …

This phase II trial is testing a drug called puxitatug samrotecan (AZD8205) in 28 adults with an aggressive form of adenoid cystic carcinoma that has spread or come back. The study aims to see if the drug is safe and effective for this specific cancer subtype. Participants will r…

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This phase 3 study compares ivonescimab, an experimental immunotherapy, to the standard drug pembrolizumab in 780 people with advanced non-small cell lung cancer that has high PD-L1 levels. Participants receive one of the two drugs as their first treatment. The study measures how…

This Phase 3 trial tests whether adding an experimental oral drug called atebimetinib to a modified chemotherapy regimen helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standa…

This early-phase trial will test whether adding semaglutide (a GLP-1 drug used for diabetes and weight loss) to standard chemotherapy is safe and tolerable for people with metastatic pancreatic, colorectal, or liver cancer. About 30 participants will receive weekly semaglutide in…

This phase II trial is testing the drug osimertinib in 46 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants will take osimertinib …

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This phase II trial tests whether adding the immunotherapy cemiplimab to the targeted drug cabozantinib works better than cabozantinib alone for advanced adrenocortical cancer. About 48 adolescents and adults whose cancer has spread or cannot be removed will take part. The study …

This phase II trial tests whether adding an experimental drug called PDS01ADC to standard radiation and hormone therapy can help the immune system fight prostate cancer. About 65 men with high- or intermediate-risk prostate cancer that hasn't spread will take part. Some will get …

This study tests a new drug called BNT324 against standard chemotherapy (docetaxel) in men with metastatic castration-resistant prostate cancer that has progressed after hormone therapy. The goal is to see if BNT324 helps patients live longer without their cancer worsening. About…

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This early-phase trial is testing whether adding an experimental drug called ZEN003694 to two approved cancer drugs (cetuximab and encorafenib) can help patients with a specific type of advanced colorectal cancer that has not responded to prior treatments. The study involves 30 a…

This study tests whether adding the drug saruparib to standard radiation and hormone therapy can delay the spread of cancer in 700 men with high-risk prostate cancer that has a BRCA gene mutation. Participants will receive either saruparib or a placebo alongside their usual treat…

This phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can shrink advanced squamous cell cancers of the nasal cavity and sinuses better than chemotherapy alone. About 35 adults with newly diagnosed, untreated stage II to IVb disease …

This early-phase trial tests giving radiation therapy before surgery to people whose adrenal cancer has come back. The goal is to find a safe radiation dose and see if it helps shrink tumors before removal. About 32 adults with resectable recurrent ACC will receive daily radiatio…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This phase II trial tests whether adding precise, high-dose radiation (SABR) to the main kidney tumor improves outcomes for people with metastatic kidney cancer that cannot be surgically removed. Participants receive standard immunotherapy drugs (avelumab, axitinib, or cabozantin…

This phase 2 trial tests enasidenib, a daily pill that targets the IDH2 gene mutation, in 40 adults with rare cancers of the nasal cavity or skull base that have spread or come back. Participants take the drug once daily in 28-day cycles, and researchers will track how long the c…

This early-stage study is testing an experimental oral drug, VVD-133214, in people with advanced solid tumors that have specific genetic features (MSI or dMMR). The drug works by blocking a protein that helps these cancers grow. The study will check safety and how well the drug w…

This phase 2 trial is testing whether giving the immunotherapy drug tislelizumab every 2 weeks or every 4 weeks, alongside standard chemotherapy, is safe and effective for Japanese patients with advanced esophageal cancer that cannot be removed by surgery. The study aims to find …

This study tests whether adding an experimental mRNA vaccine (V940) to the immunotherapy drug pembrolizumab (Keytruda) can keep lung cancer from returning after surgery. It includes 680 people with stage II to IIIB non-small cell lung cancer whose tumors did not fully respond to …

This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…

This phase 3 trial is testing whether adding the targeted drug ribociclib to standard hormone therapy can help prevent invasive breast cancer from returning in people with HR+ HER2- early breast cancer. About 1,400 participants will receive the combination for up to 3 years. The …

This study tests a new combination of two drugs (becotatug vedotin and pucotenlimab) in 20 adults with advanced penile cancer that has spread and is EGFR-positive. Participants must have failed or be unable to tolerate chemotherapy. The goal is to see if the treatment can shrink …

This study tests a new drug, AMO959, combined with a targeted radiation therapy (Pluvicto) and a hormone therapy in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has stopped responding to prior hormone treatment. The trial has two phases: first t…

This early-stage trial tests a new oral drug called AQUA07, alone or with another drug (lorlatinib), in about 102 people with ALK-positive non-small cell lung cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see how the bod…

This phase III trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can prevent breast cancer from returning in people with a specific high-risk type of hormone receptor-positive, HER2-negative breast cancer. About 3,680 participants with sta…

This study tests a drug called NBTXR3 given with radiation therapy for people with locally-advanced non-small cell lung cancer who cannot have chemotherapy or surgery. The goal is to see if the combination is safe and helps control the cancer. About 40 adults with stage I to III …

This phase II trial is testing whether the drug olaparib can help prevent pancreatic cancer from coming back in people who have already had surgery and chemotherapy and carry a BRCA1, BRCA2, or PALB2 mutation. Olaparib is a targeted therapy that blocks a repair enzyme cancer cell…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

Researchers are testing a combination of two experimental drugs, JANX013 and JANX007, in men with metastatic castration-resistant prostate cancer, an advanced form that keeps growing despite hormone-lowering treatment. The Phase 1 trial gives both drugs by intravenous infusion to…

Researchers are testing tarlatamab in people with advanced extrapulmonary small cell carcinoma or neuroendocrine carcinoma that has worsened after platinum-based chemotherapy. These rare cancers often carry high levels of a protein called DLL3, which tarlatamab targets by linking…

This trial tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer from growing. About 45 adults whose cancer responded to initial chemo-immunotherapy will receive the combi…

This trial investigates whether high doses of testosterone can shrink tumors in men with metastatic prostate cancer that no longer responds to standard hormone therapy and has mutations in DNA repair genes like ATM or CDK12. Participants receive monthly injections of high-dose te…

This phase 3 trial is testing whether tarlatamab, an immunotherapy drug, can be given as a quick injection under the skin instead of a slow intravenous drip for people with relapsed extensive-stage small cell lung cancer. The study will compare the two methods to see if the injec…

This Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive…

This study is testing whether combining a targeted drug (abemaciclib) with precise radiation (stereotactic radiosurgery) can better control brain tumors in people with a common type of breast cancer (HR+/HER2-). About 31 participants will receive both treatments along with hormon…

This phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…

This phase II trial is testing two radioactive drugs, 225Ac-PSMA-617 and 177Lu-PSMA-617, combined with precise radiation therapy for prostate cancer that has returned and spread to a few spots in the body. The drugs target a protein on cancer cells and deliver radiation to kill t…

This trial tests an experimental daily pill, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. Participants must have already tried chemotherapy and an immunotherapy drug. The study looks at whether the drug can shri…

Researchers are testing whether a chemotherapy combination called gemcitabine and carboplatin can help people with advanced urothelial cancer whose disease has worsened after treatment with enfortumab vedotin and pembrolizumab. The trial enrolls about 55 participants who receive …

Researchers are testing whether dalpiciclib, a targeted cancer drug, combined with toremifene, a hormonal therapy, can slow the growth of advanced HR-positive, HER2-negative breast cancer when used as a first-line treatment. The trial plans to enroll 36 women who have not yet rec…

This phase II trial is testing a focused, high-dose radiation therapy (SBRT) given in just two sessions for men with early-stage prostate cancer that hasn't spread. The goal is to see if this approach can destroy the tumor while avoiding the side effects of treating the whole pro…

This phase 2 trial is testing whether adding an immunotherapy drug (adebrelimab) to a chemotherapy combo (NALIRIFOX) and radiation can improve outcomes for people with a certain type of locally advanced rectal cancer (pMMR/MSS). About 84 participants will be randomly assigned to …

This Phase 3 trial tests whether a targeted therapy called sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer without their cancer growing. About 900 participants who have finished initial chemotherapy will…

This phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (MK-2870) to the immunotherapy pembrolizumab can better prevent breast cancer from coming back in people with triple-negative breast cancer who still had tumor after initial treatment. About 1,5…

Researchers are testing whether combining microwave ablation with infusions of a patient's own expanded immune cells helps people with small liver tumors. The trial enrolls adults with up to three tumors, each no larger than 5 cm, who are not eligible for surgery. After ablation,…

This study tests a drug called SMS001, a new version of the chemotherapy paclitaxel, in 42 people with non-small cell lung cancer (stages Ib to IIIa). The goal is to see if a single dose after surgery can safely prevent the cancer from coming back. Researchers will monitor side e…

Researchers are testing whether adding two immunotherapy drugs, durvalumab and tremelimumab, to focused radiation before surgery changes the immune cell makeup inside liver tumors. The trial enrolls 30 people with a single liver tumor that can be removed surgically. Everyone rece…

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with various types of breast cancer (…

This phase 3 trial is testing whether the immunotherapy drug durvalumab, given after surgery, can prevent early-stage non-small cell lung cancer from coming back. About 306 participants who have had their tumor completely removed will be randomly assigned to receive durvalumab or…

This phase 2 trial tests two antibody-drug conjugates (ADCs) — R-DXD and I-DXD — against standard chemotherapy in 144 people with advanced squamous non-small cell lung cancer that has worsened after initial treatment. ADCs are like guided missiles that deliver a cancer-killing dr…

This early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells carrying a specific marker (GPNMB). The study enrolls 30 adults in Canada with advanced alveolar soft part sar…

This phase 3 trial tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer compared to pembrolizumab alone. The study enrolls about 614 adults whose tumors have high PD-L1 lev…

This phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (sac-TMT) to standard immunotherapy (pembrolizumab) and a targeted therapy (bevacizumab) helps people with metastatic cervical cancer live longer. About 1,000 participants whose cancer has sprea…

This study investigates whether precisely targeted radiotherapy can delay the need for stronger drugs in men with prostate cancer that has started to grow in a few new spots while on systemic therapy. Participants have metastatic hormone-sensitive or castration-resistant prostate…

This study tests a new drug called ifinatamab deruxtecan (I-DXd), given alone or with other treatments, in men with metastatic castration-resistant prostate cancer (mCRPC) that has worsened despite hormone therapy. The trial aims to find safe doses and see if the drug can lower P…

This study tests a new medicine, PF-08634404, in adults with advanced kidney cancer that has spread. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer drugs. About 224 participants who have not had prior treatment for their advanced…

This phase 2 trial tests whether giving a powerful chemotherapy regimen called NALIRIFOX along with targeted radiation and the drug capecitabine can shrink pancreatic tumors enough to allow successful surgery. The study enrolls 60 people with borderline resectable or locally adva…

This phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kapo…

This study tests whether a daily pill called zongertinib can help prevent lung cancer from coming back in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. All participants have had surgery to remove their tumor and standard che…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This early-stage trial is testing a new drug called IM-1617 in people with advanced solid tumors (cancers that have spread or can't be removed by surgery). The study has two parts: first, finding a safe dose, then testing that dose in more people to see how well it works and how …

Researchers are comparing two sequences of treatment for metastatic castration-resistant prostate cancer that carries certain DNA repair gene mutations. Participants receive either carboplatin first and olaparib second, or olaparib first and carboplatin second, switching after th…

Researchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…

This Phase 3 trial tests whether the drug BNT323 (trastuzumab pamirtecan) works better than standard chemotherapy for people with recurrent endometrial cancer that expresses HER2. About 480 participants will be split into two groups based on their HER2 levels. The study measures …

This early-phase trial tests a combination of three drugs—enfortumab vedotin, pembrolizumab, and quemliclustat—in people with advanced bladder or urinary tract cancer that has spread or cannot be removed by surgery. The goal is to see if the combination is safe and effective. The…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This trial tests whether a high-intensity interval training (HIIT) program can help head and neck cancer patients maintain or improve muscle mass after chemoradiotherapy. Researchers will use imaging and blood tests to see if changes in muscle and inflammation markers can predict…

This study tests a new way to deliver radiation therapy for early-stage prostate cancer. Instead of two separate sessions days apart, both radiation doses are given just three hours apart on the same day. The goal is to see if this is safe and could make treatment more convenient…

This study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard treatments (abiraterone or enzalutamide) in about 1,300 men with metastatic castration-resistant prostate cancer that got worse after one prior hormone therapy. The goal is to s…

This study tests whether taking special gut bacteria capsules (RMT) alongside standard chemotherapy and immunotherapy can help control advanced lung cancer. About 82 people with untreated non-small cell lung cancer will receive either RMT or a placebo. The goal is to see if the b…

This study tests a new drug called HRS-5041, taken as a pill, combined with other cancer treatments for men with advanced prostate cancer. The goal is to see if the combination is safe and helps control the cancer. About 100 men aged 18 to 80 will take part. The study is currentl…

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This phase 3 trial tests whether the experimental drug sacituzumab tirumotecan helps people with advanced bladder cancer live longer than standard chemotherapy. About 590 participants whose cancer worsened after prior treatments will receive either the new drug or one of several …

This study tests a healthy eating program that encourages people with early-stage bladder cancer to eat more cruciferous vegetables like broccoli, kale, and cabbage. These veggies contain natural compounds that may help fight cancer cells. Researchers want to see if this diet cha…

This phase 3 trial tests whether adding the experimental drug BNT327 to standard chemotherapy helps people with advanced triple-negative breast cancer (TNBC) live longer without their cancer growing. Participants have TNBC that cannot be treated with current PD(L)1 immunotherapie…

This study tests whether giving two drugs (enfortumab vedotin and pembrolizumab) before bladder cancer surgery can eliminate cancer in the lymph nodes and shrink tumors. About 23 adults with advanced bladder cancer that has spread to lymph nodes will receive the combination befor…

This study is testing a drug called patritumab deruxtecan in children whose liver or muscle cancers have returned or not responded to treatment. The drug works like a smart bomb, attaching to a protein on cancer cells to deliver a toxic payload. The trial will check if it is safe…

This Phase 2 trial tests whether combining lurbinectedin (Zepzelca) with durvalumab (Imfinzi) as maintenance therapy can delay cancer growth in people with extensive-stage small-cell lung cancer whose disease has not worsened after initial chemotherapy plus durvalumab. About 50 p…

This study tests experimental drug combinations for people with advanced kidney cancer (clear cell type) that came back during or within 2 years of finishing immunotherapy. About 140 participants will receive these combinations to see if they are safe and can shrink tumors. The g…

This clinical trial is testing an experimental drug called opevesostat (MK-5684), either alone or combined with other cancer drugs, in people with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The study involves 220 participants and has t…

This early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…

This study tests a combination of the drug enfortumab vedotin and radiation therapy given before surgery for muscle-invasive bladder cancer. It is for patients who cannot receive standard cisplatin chemotherapy. The trial will test three different schedules of the drug and radiat…

This study tests a drug called I-DXd in 60 people with advanced esophageal cancer that has worsened after prior treatments. I-DXd is designed to attach to cancer cells and deliver a toxic payload to destroy them. The main goal is to see how many patients' tumors shrink or disappe…

This early-stage study tests a new treatment for people with ovarian cancer that has come back. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack a protein (FSHR) found on cancer cells. The main goal is to check the safety of these…

This study tests a new drug, setidegrasib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if setidegrasib can keep the cancer from growing longer and help people live longer…

This study tests a new drug called YL201 combined with atezolizumab in people with advanced small cell lung cancer. The goal is to find safe doses and see if the combination helps control the disease. About 118 adults who have not had prior treatment for this cancer will take par…

This phase III trial tests whether adding the immunotherapy drug serplulimab to standard induction chemotherapy can allow patients with advanced nasopharyngeal cancer to skip concurrent chemotherapy during radiation. The study plans to enroll 456 adults aged 18-65 with stage II-I…

This study is testing a new biologic drug called sacituzumab tirumotecan (MK-2870), alone or with chemotherapy, in people with advanced colorectal, pancreatic, or biliary tract cancers that cannot be removed by surgery. The main goals are to check safety and see if tumors shrink.…

This study compares two radiotherapy schedules for people with head and neck cancer who begin radiation more than 6 weeks after surgery. One group gets standard treatment (5 days a week), the other gets an accelerated schedule (6 days a week). The goal is to see if the faster sch…

This study tests whether adding an experimental drug (EIK1001) to standard immunotherapy and chemotherapy helps people with stage 4 non-small cell lung cancer live longer or slow tumor growth. About 750 adults whose cancer has spread will receive either the new combination or a p…

This study tests whether adding sacituzumab tirumotecan (Sac-TMT) to pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without the cancer getting worse. About 1,100 participants with a specific type of endometrial cancer (pMMR) will receive eith…

This study is for women aged 51 or older whose breast cancer has returned or who have a new cancer in the same breast. The goal is to see if giving a focused, short course of radiation before surgery is safe and effective enough to allow breast-conserving treatment instead of mas…

This study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can help prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and imm…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

This study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It compares a new targeted drug, ifinatamab deruxtecan, to standard chemotherapy (docetaxel) to see which helps people live longer a…

This study tests new drug combinations (including an antibody-drug conjugate) with the immunotherapy pembrolizumab, with or without chemotherapy, for people with advanced esophageal cancer that cannot be removed by surgery or has spread. About 298 participants will join to see if…

This early-phase trial is testing a new oral drug called RMC-5127, alone or combined with other drugs, in adults with advanced solid tumors that have a specific KRAS G12V mutation. The study includes people with lung, colorectal, and pancreatic cancers who have already tried stan…

This phase 2 trial tests a new approach for patients with resectable head and neck squamous cell carcinoma. It combines an engineered mitochondrial vaccine (IMP3-Mito) with an immune checkpoint inhibitor (PD-1 inhibitor) given before and after surgery. The goal is to improve the …

Researchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…

This study tests whether two common heart medications—atorvastatin (a statin) and lisinopril (an ACE inhibitor)—can prevent or reduce heart damage caused by radiation therapy for chest cancers like breast, lung, and esophageal cancer. About 60 adults receiving chest radiation wil…

This trial tests whether adding two drugs (surufatinib and camrelizumab) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 502 adults who have not had prior treatment for their advanced cancer will be randomly assigned to the new combo or …

This phase II trial is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, works better than nivolumab alone for women with recurrent endometrial cancer that has a specific DNA repair defect (dMMR). About 81 participants will receive either the combinatio…

Researchers at Emory University are testing intensity-modulated proton therapy (IMPT) for people with small cell lung cancer. Proton therapy delivers radiation to tumors while reducing exposure to nearby healthy organs like the heart. The study enrolls 30 adults with limited or e…

This Phase 3 trial is testing whether adding the drug zanzalintinib to belzutifan helps people with advanced kidney cancer live longer and keep the cancer from growing. About 758 participants who have already tried standard treatments will receive either the combination or belzut…

This early-stage study is testing a new drug called BGB-B2033, alone or with other drugs, in people with advanced liver, stomach, or lung cancers. The goal is to see if it is safe and how well it works. About 392 participants will take part.

This study tests whether adding a virus-based drug (pelareorep) to standard chemotherapy can help people with a specific type of advanced colorectal cancer that has stopped responding to initial treatment. About 60 adults whose cancer has spread and has certain genetic features (…

Researchers are testing whether giving lenvatinib and pembrolizumab before surgery can shrink advanced kidney cancer and the tumor clot that extends into the main vein from the kidney. The trial enrolls 30 adults with stage III or IV renal cell carcinoma and a level II to IV infe…

This study tests an experimental gene therapy called quaratusugene ozeplasmid (Reqorsa) combined with the drug osimertinib (Tagrisso) in people with advanced EGFR-mutant non-small cell lung cancer whose cancer has stopped responding to osimertinib alone. The gene therapy delivers…

This phase II trial tests whether a drug called BIO 300, made from a soy compound, can prevent severe lung inflammation (pneumonitis) in people with early-stage non-small cell lung cancer who also have interstitial lung disease. About 25 participants will receive BIO 300 along wi…

This phase 2 trial is testing whether a targeted antibody-drug conjugate called sacituzumab tirumotecan, given alone or together with the immunotherapy pembrolizumab, can shrink tumors in people with ovarian clear cell carcinoma that has returned after prior immunotherapy. The st…

This phase II trial tests whether adding an experimental drug called INBRX-106 to the immunotherapy pembrolizumab (Keytruda) can shrink tumors in people with stage II or III triple-negative breast cancer before they receive standard chemotherapy. The study will enroll 12 adults w…

This study tests a new treatment called iC9-CAR.CSPG4 T cells for people with head and neck cancer that has come back after standard treatments. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to fin…

This Phase 2 trial tests whether combining pembrolizumab (an immunotherapy) with aldesleukin (IL-2) can shrink tumors in people with advanced melanoma or kidney cancer that hasn't responded to prior treatments. About 78 adults will receive two cycles of the combo in the hospital,…

This phase II trial tests whether adding the immunotherapy drug relatlimab to standard nivolumab maintenance therapy can extend the time before cancer grows or spreads in patients with recurrent or metastatic nasopharyngeal cancer linked to Epstein-Barr virus. Participants first …

This clinical trial is investigating whether an experimental drug called SHR-9839, when used alone or combined with standard chemotherapy and an immunotherapy drug, can help people with advanced esophageal squamous cell carcinoma. The study will include about 84 adults aged 18 to…

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

This phase 2 trial tests whether adding two experimental drugs, imzokitug and pumitamig, to standard chemotherapy helps people with advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. About 160 participants will receive either the three-drug combination …

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This early-phase trial is testing an experimental drug called BMS-986504 alongside standard cancer treatments in 60 people with advanced cancers that have lost a gene called MTAP. The cancers include mesothelioma, stomach/esophageal cancer, and bladder cancer. The main goal is to…

This phase 2 trial tests proton beam radiation therapy in 20 adults with non-small cell lung cancer that has spread to chest lymph nodes (N2) and has been surgically removed. Proton therapy targets cancer cells while sparing healthy tissue, potentially reducing recurrence risk. R…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This study tests an experimental pill called VS-7375, designed to block a specific cancer-driving protein (KRAS G12D). The trial includes people with metastatic colorectal cancer that has this mutation. Some participants receive VS-7375 alone, others get it combined with an antib…

Researchers are testing whether adding inhaled manganese chloride to standard chemotherapy and an anti-PD-1 immunotherapy can help people with advanced ovarian cancer that has worsened after at least two prior treatments. The trial enrolls about 120 participants and randomly assi…

This study looks at whether adding radiation to the liver can improve outcomes for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer that has spread. About 60 adults with at least one liver tumor 3 cm or larger will receive either standard therapy a…

This phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

This study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…

This study tests a drug called adagrasib, alone or with pembrolizumab (an immunotherapy), in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the combination shrinks tumors and helps people live longer without t…

This early-phase trial is testing a new drug called GSK5471713 in 54 men with metastatic castration-resistant prostate cancer that has worsened despite standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors or lower PSA levels. It is the fir…

This early-stage trial is testing a new treatment called GB-5267 for people with ovarian cancer that no longer responds to platinum-based chemotherapy. GB-5267 is a type of immune cell therapy (CAR T cell) that has been engineered to better target cancer cells and includes an ext…

This early-stage trial is testing a new approach for people with advanced non-small cell lung cancer that has specific gene changes (EGFR, ALK, ROS1, or HER2). Doctors take immune cells from the patient's own tumor, boost them in the lab with a molecule called CD40L, and then giv…

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…

This phase 3 trial tests whether injecting the drug cemiplimab directly into early-stage skin cancer tumors can work as well as surgery. About 369 people with small tumors on the head, neck, hand, or shin will be randomly assigned to get either the injections or standard surgery.…

This study tests whether combining two drugs, tepotinib and ivonescimab, is safe and works for people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. About 16 participants will try different doses to find the one with the fewes…

This study tests an experimental oral drug called zongertinib, which blocks HER2, a protein that fuels cancer growth. It is given alone or with other cancer drugs to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and not responded to prior treatm…

Researchers are testing a new drug, VVD-133214, combined with pembrolizumab in people with advanced colorectal cancer that has MSI and/or dMMR. These tumors rely on a protein called Werner helicase to survive, and VVD-133214 is designed to block it. The trial compares the combina…

Researchers are testing a radiation schedule that delivers higher doses per session and more sessions per day for non-small cell lung cancer that grows quickly. The trial enrolls adults with confirmed high-proliferation NSCLC who are planned for chest radiotherapy, regardless of …

This phase 3 trial compares a new targeted drug, telisotuzumab vedotin, to the standard chemotherapy docetaxel in adults with a specific type of advanced non-small cell lung cancer that has a high level of a protein called c-Met. About 698 participants worldwide will receive eith…

Researchers are testing sacituzumab govitecan, an antibody-drug conjugate, in adults with advanced differentiated or anaplastic thyroid cancer that has stopped responding to radioactive iodine. The drug targets TROP-2, a protein found at high levels on these cancer cells. The tri…

This phase 2 trial is testing whether adding two extra drugs—bevacizumab and sintilimab—to the usual combination of irinotecan and cetuximab can shrink tumors in people with advanced colorectal cancer that no longer responds to irinotecan. The study enrolls 160 adults with RAS wi…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

Researchers are testing an experimental injectable drug called XNW28012 in people with metastatic pancreatic cancer that has worsened after two standard chemotherapy regimens. The phase III trial plans to enroll 226 adults and randomly assigns them in a 2:1 ratio to receive eithe…

This study tests whether two drugs, abemaciclib and letrozole, can help keep advanced or recurrent endometrial cancer from getting worse. About 32 people with a specific type of estrogen-sensitive cancer will take these pills daily after initial treatment. The goal is to see if t…

This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…

This trial tests whether adding an experimental drug called culmerciclib to standard hormone therapy can shrink tumors more effectively in women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. Participants receive either the combination or hormone therap…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This early-phase trial is testing a gene therapy called nadofaragene firadenovec for people with low-grade upper tract urothelial cancer. The drug is instilled directly into the kidney's renal pelvis. The study aims to see if it is safe and can eliminate the cancer. Twenty adults…

This study tests whether adding the experimental drug INCA33890 to standard chemotherapy and bevacizumab helps people with metastatic colorectal cancer that is microsatellite stable (a type that doesn't respond well to immunotherapy). About 700 adults who have not had prior treat…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This phase 3 trial tests whether adding a gene therapy called IMNN-001 (given into the abdomen) to standard chemotherapy helps people with advanced ovarian, fallopian tube, or peritoneal cancer live longer. About 500 newly diagnosed patients will be randomly assigned to receive e…

This study tests a vaccine made from candida (a type of yeast) to see if it can reduce the risk of head and neck cancer coming back. About 100 adults who have finished cancer treatment and are currently cancer-free will receive either the vaccine or a placebo over two years. The …

This clinical trial is testing a new biological therapy called GAIA-102, alone or combined with the immunotherapy pembrolizumab, for people with advanced stomach or pancreatic cancer that has spread and caused fluid buildup in the abdomen (malignant ascites). The study has two pa…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This study tests whether a probiotic called EXE-346 can help treat anal high-grade squamous intraepithelial lesions (HSIL) and reduce persistent high-risk HPV infection in people living with HIV. The trial will enroll 90 participants who will take the probiotic or a placebo daily…

This early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug throug…

This study tests whether a daily pill called isoquercetin, made from a plant compound, can reduce blood markers linked to clot risk in people with ovarian cancer. About 90 participants receiving chemotherapy will take either isoquercetin or a placebo for up to 6 weeks. The goal i…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This Phase 3 trial tests whether elacestrant, a new hormone therapy, can prevent distant metastasis better than standard hormone therapies in 220 patients with ER+/HER2- breast cancer whose blood tests show signs of cancer DNA (ctDNA) but no visible spread. Participants are rando…

Researchers are comparing a new combination of disitamab vedotin, sintilimab, and S-1 against the standard regimen of trastuzumab plus chemotherapy, with or without sintilimab, for people with advanced HER2-positive gastric or gastroesophageal junction cancer. The trial enrolls a…

This study tests a new drug called BGB-43395 combined with letrozole against standard CDK4/6 inhibitor drugs (abemaciclib, palbociclib, or ribociclib) plus letrozole for people with advanced or metastatic HR+/HER2- breast cancer who have not had prior treatment for advanced disea…

This study tests a new drug called INCB123667 in 160 people with a type of ovarian cancer that no longer responds to platinum chemotherapy and has high levels of a protein called cyclin E1. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants…

This study tests a new drug called dabogratinib in 230 adults with a rare, low-grade cancer in the upper part of the urinary tract. The goal is to see if the drug can make the cancer disappear completely within 6 months. Participants take the drug by mouth and are monitored for s…

This study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This Phase 3 trial tests a new oral drug, INCB123667, against standard chemotherapy in 466 people with platinum-resistant ovarian cancer that overexpresses cyclin E1. The goal is to see if the new drug can delay cancer growth or improve survival. Participants will be randomly ass…

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…

This named patient program gives doctors controlled, pre-approval access to a mitomycin gel called JELMYTO for specific patients with cancer of the renal pelvis or ureter. It is for people in select countries where the treatment is not yet approved and who have exhausted other op…

This Phase 3 trial tests whether adding obrixtamig to standard chemotherapy helps people with advanced extrapulmonary neuroendocrine cancer live longer. About 390 adults will be randomly assigned to get either the combo or chemo alone. Obrixtamig is designed to help the immune sy…

This early-phase trial tests a nasal spray called NEO100 (a purified natural compound) in 12 children with certain aggressive brain tumors. The goal is to see if it's safe, find the best dose, and check if the drug reaches the tumor. Participants will receive increasing doses, an…

This study tests a new drug called elacestrant against standard hormone therapy in people with a certain type of early breast cancer (ER+/HER2-) that has spread to lymph nodes and has a high chance of returning. About 4,220 participants will be randomly assigned to receive either…

This early-phase trial is testing a new drug called xaluritamig (AMG 509) in 40 adults with metastatic castration-resistant prostate cancer, a type that has spread and no longer responds to hormone therapy. The main goal is to check the drug's safety and how it moves through the …

This phase 2 trial is testing three different doses of an investigational drug called telisotuzumab vedotin in about 150 adults with a specific type of advanced lung cancer (non-small cell lung cancer that has high levels of a protein called c-Met and no EGFR mutation). The drug …

This early-stage trial tests a new drug that delivers radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has stopped responding to hormone therapy. The study will check for side effects and see if the drug …

This phase II study is testing whether women with certain types of early-stage endometrial cancer can safely receive less aggressive treatment after surgery. The approach is guided by the tumor's molecular profile—either POLE-mutated or p53 wildtype/NSMP. Around 393 participants …

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This phase 2 trial is testing whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with lenvatinib, radiotherapy, and chemotherapy delivered directly to the liver can help people with hepatocellular carcinoma that has spread into the portal vein. The study aim…

This study compares a newer, precise radiation method called stereotactic body radiotherapy (SBRT) with standard radiation therapy for people with advanced head and neck cancer who cannot have curative treatment. About 196 adults will be randomly assigned to one of the two radiat…

This study is testing whether the immunotherapy drug dostarlimab (TSR-042), followed by standard chemoradiation and surgery, can effectively treat advanced mismatch repair deficient (dMMR) solid tumors. About 212 adults with locally advanced dMMR cancers will receive the drug int…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-phase trial is testing two drugs, osimertinib and tegavivint, as a first treatment for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC that has spread). The goal is to find the best dose and see if the combination is safe and shrinks tumors. Abou…

This study tests a combination of two immunotherapy drugs (iparomlimab and toripalimab) plus bevacizumab and chemotherapy as a first treatment for advanced biliary tract cancer. It involves 32 adults aged 18-75 who have not had prior treatment for their advanced cancer. The goal …

This study tests a new drug called daraxonrasib in people with pancreatic cancer who have already had surgery and chemotherapy. The goal is to see if taking the drug can delay or prevent the cancer from returning compared to just watching and waiting. About 500 adults will be ran…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This study tests whether adding the experimental drug IMNN-001 to standard chemotherapy and bevacizumab can better eliminate remaining cancer in people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. About 30 participants will be randomly assi…

This Phase 3 trial is testing whether adding a new targeted pill (INCB161734) to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS G12D mutation) live longer. About 588 participants who have not had prior treatment for metastatic disease …

Researchers are testing two experimental oral drugs, TT-10 and TT-4, in adults with advanced solid tumors such as kidney, prostate, and lung cancers that have worsened after standard treatment or cannot receive it. The drugs block adenosine receptors, which tumors use to quiet th…

This study tests a new drug, telisotuzumab adizutecan, in people with advanced EGFR-mutated non-small cell lung cancer whose cancer has progressed after a third-generation targeted therapy. About 430 adults will receive either the new drug or standard care. The goal is to see if …

This phase 2 trial tests whether adding tafolecimab (a cholesterol-lowering drug) to standard chemotherapy and the immunotherapy sintilimab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 40 adults who have not had prior tr…

This study tests a new combination of two drugs (trastuzumab deruxtecan and pembrolizumab) against standard chemotherapy plus pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of HER2 and low PD-L1. About 686 adults will t…

This study is testing whether memantine, a drug currently used for Alzheimer's disease, can help slow the growth of liver cancer in people with advanced cirrhosis. The trial will enroll 12 adults with liver cancer that cannot be removed by surgery and who are not candidates for s…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This phase 3 trial tests whether adding the targeted drug zolbetuximab to standard immunotherapy (pembrolizumab) and chemotherapy can help people with advanced stomach or gastroesophageal junction (GEJ) cancer live longer. The study enrolls 500 adults whose tumors have specific m…

This study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or usual care (topotecan, lurbinectedin, or amrubicin) to see which works better. The goal is to s…

This early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…

This study tests a gene therapy called aglatimagene besadenovec, given with valacyclovir, in 45 men with intermediate-risk prostate cancer who will also receive radiation. The main goal is to see how the therapy spreads in the body and to measure immune responses and tumor marker…

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This study is for people with liver cancer that cannot be removed by surgery. Researchers want to find the exact amount of radiation needed to completely destroy the tumor using a special procedure called Y90 radioembolization. About 30 adults will take part to help improve treat…

This study is for men with prostate cancer that has spread to a few other parts of the body at diagnosis. It tests whether adding radiation therapy directly to those cancer spots (called metastasis-directed radiotherapy) can help keep the cancer under control longer than the usua…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This study is for people with HPV-related throat cancer who have surgery to remove the tumor. Normally, some patients also get radiation afterward to lower the risk of cancer coming back. This trial tests whether it's safe to skip that radiation if a blood test two weeks after su…

This phase 2 trial is testing an experimental drug called ubamatamab, alone or combined with other cancer drugs, in 220 people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The study aims to see how…

This phase 2 trial tests whether the drug TPST-1495 can reduce the number and size of polyps in the small bowel and colon of people with familial adenomatous polyposis (FAP), an inherited condition that greatly raises colon cancer risk. About 38 participants will take the drug by…

This study tests a new drug called pumitamig, alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. The trial includes 198 participants who have not had prior cancer treatment. The goal is to see if the drugs are safe and…

This study compares two surgical approaches for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have received chemotherapy before surgery. One group will have minimally invasive surgery (small incisions), and the other will have standard open surger…

This study tests an experimental drug called HRX215 in people who had part of their liver removed because colon cancer spread there. The drug is meant to help the liver grow back and work better after surgery. About 80 adults will take either HRX215 or a placebo for 28 days, and …

This study tests a new medicine called PF-08634404, given alone or with chemotherapy, for adults with early or locally advanced non-small cell lung cancer. The trial has three parts: before surgery, after surgery if cancer remains, or after chemoradiation. Researchers will check …

This phase 2 trial tests whether adding cediranib or ceralasertib to olaparib can overcome resistance in BRCA-mutated advanced breast cancer. About 60 participants with HER2-negative, BRCA-positive tumors that have progressed on prior therapy will receive one of the two drug comb…

This study tests whether adding an experimental treatment (V940) to standard BCG therapy helps people with high-risk non-muscle invasive bladder cancer live longer without their cancer returning. About 308 adults will be randomly assigned to get either V940 plus BCG or BCG alone.…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This early-stage study is testing a new drug called calderasib (MK-1084) in people with advanced solid tumors that have a specific KRAS G12C mutation. The drug is given alone or combined with other cancer treatments. The main goals are to check safety and find the right dose. Abo…

This study tests an experimental drug called BMS-986525, given alone or with the immunotherapy nivolumab (Opdivo), in 240 people whose small cell lung cancer has returned or stopped responding to standard platinum-based chemotherapy. The main goals are to check safety and tolerab…

This early-phase trial is testing a new drug called BGB-21447, which blocks a protein that helps cancer cells survive. It is given together with standard hormone therapy (fulvestrant) and sometimes another targeted drug (BGB-43395). The study involves 120 adults with HR+/HER2- me…

This Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…

Researchers are testing whether adding an experimental drug called 2141-V11 to standard immunotherapy is safe for people with advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma. Participants receive injections of 2141-V11 directly into their tumors along wi…

This phase 3 trial is testing whether a combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of…

This early-phase study tests whether adding the experimental drug ipatasertib to standard chemotherapy and radiation is safe and effective for people with advanced head and neck cancer. Ipatasertib may help stop cancer cell growth. About 46 participants will receive the combinati…

This Phase 3 trial tests whether adding the targeted drug calderasib to the immunotherapy pembrolizumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 675 participants with advanced non-squamous non-small cell lung cance…

This study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare …

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

This Phase 3 trial is testing whether adding an experimental drug called calderasib (MK-1084) to standard immunotherapy (pembrolizumab) can keep non-small cell lung cancer from returning after surgery. The study enrolls 400 people with a specific KRAS G12C mutation whose cancer w…

This study tests two drugs, durvalumab and monalizumab, given together to people with a type of bladder cancer that has not gotten better with standard treatment. The goal is to see if the combination can make the cancer disappear or stop it from growing. About 60 adults will tak…

Researchers are testing whether a balloon catheter coated with the drug sirolimus can safely open narrowed coronary arteries in adults with heart disease. The balloon inflates to press the drug into the artery wall, aiming to keep the vessel open without leaving a permanent stent…

Inavolisib treats certain PIK3CA-mutated, HR-positive, HER2-negative breast cancers but can raise blood sugar. Researchers at Tianjin Medical University Cancer Institute and Hospital are studying whether matching blood sugar monitoring and preventive metformin to each patient's r…

Researchers are testing whether a combination of two drugs, atezolizumab and bevacizumab, can clear tiny amounts of cancer DNA from the blood of people whose gastrointestinal cancer was treated with curative intent. The trial enrolls 20 adults with colon, rectal, gastric, pancrea…

People with high-grade non-muscle-invasive bladder cancer often receive BCG immunotherapy, but some cancers stop responding. The standard next step is surgery to remove the bladder, which many patients cannot or choose not to have. This trial tests whether radiation to the whole …

Researchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…

Researchers are testing whether adding the drug inavolisib to hormone therapy and the antibody combination trastuzumab plus pertuzumab helps shrink HER2-positive, HR-positive breast tumors before surgery. The trial enrolls 170 patients with early-stage breast cancer that has a PI…

Researchers are testing whether combining abiraterone and dalpiciclib can shrink recurrent or metastatic salivary gland cancer that is AR-positive and HER-2-negative. The trial enrolls up to 36 adults who have no curative surgery or radiation options. Participants take both drugs…

Researchers are testing whether giving chemotherapy before surgery helps people with clearly resectable pancreatic head cancer or periampullary cancer live longer than going straight to surgery. The trial enrolls 262 participants and randomly assigns them to either mFOLFIRINOX ch…

Researchers are testing whether adding tislelizumab and anlotinib after chemoradiotherapy can help people with limited-stage small cell lung cancer live longer without their cancer coming back. The study enrolls adults aged 18 to 75 whose cancer has not worsened after concurrent …

Researchers are testing whether treating a few growing spots of metastatic breast cancer with surgery, radiation, or heat ablation while continuing the same systemic drug can keep the cancer under control longer. The trial enrolls people with metastatic breast cancer whose cancer…

Pancreatic ductal adenocarcinoma often returns near where it started, even after surgery. This study tests whether a more thorough operation, called total mesopancreatic excision, can improve local disease control and survival. During pancreaticoduodenectomy, surgeons remove the …

Researchers are testing whether combining SX-682, an experimental drug that blocks CXCR1 and CXCR2, with proton craniospinal irradiation is safe and effective for people with leptomeningeal disease from melanoma or non-small cell lung cancer. Participants take SX-682 by mouth twi…

Researchers are testing whether adding ivonescimab to enfortumab vedotin works better than adding pembrolizumab to enfortumab vedotin in people with locally advanced or metastatic urothelial cancer who have not yet received systemic treatment. The trial enrolls about 800 adults w…

Researchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…

Researchers are testing a combination treatment for intrahepatic cholangiocarcinoma, a type of liver cancer that cannot be removed by surgery. The study gives participants Y-90 radioembolization, which delivers radiation directly to liver tumors, followed by six cycles of the che…

Researchers are testing whether adding darolutamide to docetaxel or cabazitaxel chemotherapy helps men with metastatic castration-resistant prostate cancer whose disease has worsened on a hormone-blocking drug. The trial enrolls about 245 men and randomly assigns them to receive …

Researchers are testing whether giving becotatug vedotin, pucotenlimab, and cisplatin before surgery can shrink locally advanced EGFR-positive head and neck squamous cell carcinoma. The trial enrolls 40 adults with stage III or IV disease who have not yet received treatment. Part…

Researchers are testing whether adding oral fecal microbiota transplantation capsules can help control advanced hepatocellular carcinoma that has worsened during treatment with immune checkpoint inhibitors and tyrosine kinase inhibitors. The trial enrolls 30 adults with liver can…

Researchers test whether combining sacituzumab tirumotecan and tislelizumab can shrink advanced esophageal squamous cell carcinoma that has worsened after prior immunotherapy. The trial enrolls 28 adults whose cancer is not suitable for surgery or definitive chemoradiation. Parti…

Researchers are testing a combination of a gonadotropin-releasing hormone agonist injection and the drug letrozole in obese women with early-stage endometrial cancer that has not responded to progestin. The goal is to see if this hormone-blocking approach can shrink tumors and al…

Researchers are testing two investigational radiopharmaceuticals in adults with advanced solid tumors, including colorectal, pancreatic, biliary tract, gastric, esophageal, and head and neck cancers. First, participants receive SKL35502, an imaging agent that highlights tumors ca…

Researchers test whether a combination of GnRHa and letrozole can shrink early endometrial cancer or atypical hyperplasia in non-obese patients who have not responded to progestin therapy. The trial compares this regimen with Diane-35 plus metformin. About 80 participants receive…

Researchers are testing whether combining pembrolizumab, an immunotherapy given intravenously every three weeks, with lenvatinib, a daily oral drug, can help adults with metastatic non-small cell lung cancer that carries a RET gene rearrangement and has worsened after prior treat…

Researchers are comparing two chemotherapy approaches for people with advanced pancreatic cancer that has not worsened after three months of initial treatment with mFOLFIRINOX. One group continues mFOLFIRINOX, while the other switches to gemcitabine plus nab-paclitaxel. The trial…

Researchers are testing whether adding the blood pressure drug olmesartan to dalpiciclib and standard hormone therapy helps women with HR+/HER2- advanced breast cancer. The trial enrolls 40 women aged 18 to 75 with locally advanced or metastatic disease. Everyone receives the thr…

This trial tests whether adding radiofrequency ablation to standard chemotherapy and bile duct stenting helps patients with inoperable bile duct cancer. Radiofrequency ablation uses a catheter to deliver heat that destroys tumor tissue blocking the bile duct. Researchers compare …

Researchers are testing whether a single, concentrated dose of radiation to the tumor site can replace the usual weeks of daily radiation after breast-conserving surgery. The trial enrolls 250 women with early-stage, low-risk breast cancer that has not spread to lymph nodes. Doct…

Researchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…

Researchers are testing whether a short, focused course of radiotherapy combined with immunotherapy and chemotherapy can shrink locally advanced esophageal squamous cell carcinoma before surgery. Participants receive three cycles of camrelizumab plus nab-paclitaxel and carboplati…

Researchers are testing whether a drug called 5-aminolevulinic acid (5-ALA) can make kidney tumors glow under blue light during surgery. Adults with suspected kidney cancer take the drug by mouth before a partial nephrectomy, a procedure that removes part of the kidney. Surgeons …

This study tests whether a medication called 5-ALA, already used in brain surgery, can make upper urinary tract tumors glow under blue light during surgery. About 10 adults with known or suspected tumors will take 5-ALA before their procedure. The goal is to see if this technique…

Researchers are testing a new PET imaging tracer called 18F-HER2 Affibody to see how well it detects HER2-expressing breast cancer. The study includes 40 adults with confirmed or suspected HER2-positive breast cancer. Participants receive the tracer and then undergo a PET scan. T…

This phase 2 trial is testing whether a special PET scan tracer called 18F-DCFPyL can accurately show how prostate cancer responds to standard radiation therapy. About 130 adults with newly diagnosed, localized prostate cancer will receive the tracer and undergo PET/CT scans at s…

Researchers compare two tracers, indocyanine green (ICG) and blue patent dye, for locating lymph nodes during targeted axillary dissection in breast cancer patients who have received chemotherapy before surgery. The trial measures how often each tracer successfully identifies the…

This study is testing a new 3D automated ultrasound system called ATUSA to see how well it can image suspicious breast lesions. Up to 800 women with suspicious findings on standard imaging will get an ATUSA scan before their biopsy. The goal is to collect images and compare them …

Researchers are testing a radioactive tracer called 18F-NY104 to see how well it detects kidney cancer and other tumors that carry a protein called CAIX. About 120 people with known or suspected kidney cancer, or other CAIX-positive cancers, will receive an injection of the trace…

Researchers are testing whether advanced ultrasound techniques combined with machine learning can improve the detection and characterization of liver cancer compared to standard ultrasound. The study enrolls 200 adults who have a focal liver lesion visible on ultrasound or are in…

This phase 3 trial is testing a new type of PET scan that uses a radioactive tracer called [18F]FAPI-74 to detect whether pancreatic cancer has spread to other parts of the body. About 200 adults with pancreatic cancer will receive one dose of the tracer and then be scanned. The …

This study is testing a new type of PET/CT scan called [¹⁸F]FAPI-74 to see if it can better detect when stomach or esophageal cancer has spread to other parts of the body. About 200 adults with these cancers will receive one dose of the scan tracer and be followed for up to 3 mon…

Researchers at Ruijin Hospital are testing two PET imaging tracers, FAPI and Grazytracer, to see if they can predict how well advanced gastric cancer responds to preoperative immunotherapy. The study enrolls 120 adults with resectable or advanced gastric cancer. Participants rece…

This study tests whether a special PET scan using a radioactive tracer called 68Gallium-DOTATATE can better detect thyroid cancer that has spread and no longer responds to standard radioactive iodine therapy. About 54 adults with metastatic thyroid cancer will receive one injecti…

This study tests whether a simple urine test (Bladder EpiCheck) can safely replace some of the invasive cystoscopy procedures used to monitor non-muscle invasive bladder cancer. About 240 adults with low-grade intermediate-risk bladder cancer will be followed to compare quality o…

High-grade serous ovarian cancer is often found too late, and no screening test exists. Researchers are studying whether DNA taken from routine cervical smears can show signs of this cancer early. They use a method called shallow-coverage whole genome sequencing to look for genom…

This study looks at whether adding an MRI to the yearly mammogram can help find breast cancer earlier in women with dense breasts. Participants will have a mammogram and a risk score calculated from it. Those with a high risk score will be offered an MRI. The goal is to see if th…

This trial is testing whether advanced PET-CT scans can spot early signs of heart damage caused by standard radiation therapy for locally advanced non-small cell lung cancer. Ten adults with stage III lung cancer will receive a special PET-CT scan before and three months after th…

This study explores whether a biosensor using trained laboratory animals can detect non-small cell lung cancer (NSCLC) by smelling unique chemicals in urine. Participants include people with and without NSCLC, as well as those suspected of having it. The goal is to see if this an…

This study aims to see if a new office-based test (EsoCheck balloon and EsoGuard lab test) can accurately detect Barrett's esophagus in people who do not have chronic heartburn. Barrett's esophagus is a condition that can lead to esophageal cancer, but it is often missed in peopl…

This study tests a new PET/CT imaging agent called 68Ga-NYM032 in 232 men with suspected prostate cancer recurrence after initial treatment. Participants have rising PSA levels, and the scan aims to accurately locate any remaining cancer. The goal is to see how well the scan dete…

Researchers are evaluating a dynamic risk prediction model for severe myelosuppression in adults with nasopharyngeal carcinoma who receive systemic anticancer treatment. The model estimates the risk of grade 3 or higher anemia, low platelets, or low white blood cells during thera…

Researchers are studying whether a digital management platform can help diagnose liver cancer at an earlier stage in people with chronic liver disease. The study enrolls adults aged 18 to 75 with conditions such as chronic hepatitis B. The platform tracks patients and guides stan…

This phase 2 study tests whether a radioactive tracer called [68Ga]BED003 can improve PET/CT scans for detecting cancer in the peritoneum (the lining of the abdomen). The trial includes adults with colorectal, ovarian, gastric, pancreatic, or a type of breast cancer. Researchers …

Researchers are developing an artificial intelligence model that reads preoperative CT scans and clinical data to predict whether lung cancer associated with cystic airspaces has high-risk features. The study includes 600 patients with non-small cell lung cancer who had surgery a…

This study is testing whether routine brain MRIs can find brain metastases in stage IV breast cancer patients who have no neurological symptoms. Researchers will scan 170 participants at the start and again at 6 months or when their cancer first progresses. The goal is to see how…

Researchers are testing whether a fluorescent dye called cRGD-ZW800-1 can help surgeons see laryngeal and hypopharyngeal tumors more clearly during total laryngectomy. The trial has two parts: first, to find the best dose of the dye by measuring how brightly it lights up tumor ti…

The ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…

Researchers are studying whether a blood test called Guardant360 can measure how well cancer treatment is working in people with advanced lung, colorectal, or breast cancer. The test looks for tumor DNA that cancer cells release into the bloodstream. Participants give blood sampl…

Researchers are testing whether a 3D imaging model called 3D-PANC MSP is better than standard CT scans at showing how pancreatic tumors respond to chemotherapy before surgery. The study includes 70 patients with borderline or locally advanced pancreatic adenocarcinoma who have re…

Researchers are developing a blood test that uses DNA methylation patterns and machine learning to detect multiple types of cancer at an early stage. The PROFOUND study collects blood samples from people newly diagnosed with cancer and from people without a confirmed cancer diagn…

Researchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…

Researchers are testing a urine-based fluorescence assay to see if it can detect urological cancers in people who have blood in their urine. The study enrolls 170 adults scheduled for cystoscopy or ureteroscopy. Urine samples are collected before endoscopy and analyzed with the a…

Researchers are testing whether a combination immunotherapy called iparomlimab and tuvonralimab can prevent liver cancer from returning after surgery in patients whose tumors are at high risk of coming back. Participants receive one dose of the immunotherapy before surgery to rem…

This study looks at whether training pharmacy staff to better communicate about and manage the HPV vaccine can increase vaccination rates in children ages 9-17. About 1,900 participants, including pharmacy staff and parents, will be involved. The goal is to make it easier for fam…

This study tests whether taking a daily statin (rosuvastatin) for one year can safely prevent life-threatening blood clots in people with cancer. Current clot-preventing drugs raise bleeding risks, so a safer option is needed. The trial will enroll 4,000 adults with newly diagnos…

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

Researchers are testing whether giving targeted radiation to lung tumors before a lung transplant can create an immune response that helps the body fight cancer. The trial enrolls adults with end-stage lung disease and hard-to-treat lung cancer who need a transplant. The goal is …

This early study tests a new type of radiation therapy called ConformalFLASH, which delivers radiation at an ultra-high speed. It is for 10 adults with head and neck cancer who need a second round of radiation but cannot have surgery. The goal is to see if this fast treatment is …

This study looks at whether adding pelvic floor physical therapy before standard radiation treatment can help reduce pain and sexual problems in women with cervical, vaginal, vulvar, uterine, or anal cancer. About 20 participants will receive education on using a vaginal dilator …

This study tests an 8-week program of nutrition advice, exercise, and psychological support for people with pancreatic or esophageal cancer before they have surgery. The goal is to see if patients can complete the program and if it helps them prepare for surgery. Only 9 patients …

This study tests whether different types of massage can lower anxiety in cancer patients while they receive chemotherapy. Fifty adults who already have high anxiety and are at least one cycle into chemo will receive massage during their infusion sessions. Researchers will measure…

This study is testing whether a virtual, 8-session group therapy program can help cancer patients find meaning and reduce emotional distress. Researchers at MD Anderson Cancer Center will enroll 72 adults with a history of cancer. Participants will attend weekly 90-minute session…

This study tests whether cannabidiol (CBD) can reduce the need for strong painkillers (opioids) in people with end-stage prostate cancer that has spread and no longer responds to standard treatments. About 58 participants will receive either CBD or a placebo three times daily for…

This study tracks 50 people who choose radiofrequency ablation (RFA) for benign thyroid nodules or low-risk papillary thyroid cancer instead of surgery. Researchers will monitor long-term outcomes and quality of life using questionnaires. The goal is to see if RFA is a good alter…

This phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …

This pilot study tests whether a nurse-led, group-based virtual coping program called RESTORE is feasible and acceptable for people who have finished treatment for triple-negative breast cancer. The program teaches skills like problem-solving, relaxation, and mindfulness to help …

This Phase 3 trial tests whether the experimental drug paltusotine can reduce flushing and diarrhea in adults with carcinoid syndrome caused by neuroendocrine tumors. About 141 participants will receive either paltusotine or a placebo daily for 12 weeks. The study measures how mu…

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…

This study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…

This study tests whether a remote exercise and nutrition program is practical and acceptable for people with pancreatic cancer who are waiting for surgery. Participants will use a Fitbit, get nutrition advice, and do resistance training at home. The goal is to see if this 'prehab…

Chemotherapy often causes nausea and vomiting, which is especially hard for children. This study tests a new IV drug called NEPA (fosnetupitant/palonosetron) to prevent these side effects in kids with cancer. The trial has two parts: first, an open-label phase to find the right d…

This study tests whether an artificial intelligence (AI) app can improve quality of life, anxiety, and depression in people with cancer who are already receiving psychotherapy. About 60 participants will be randomly assigned to either get the AI app alongside their usual therapy …

Researchers compare two robotic surgery approaches for removing lung tumors in adults with non-small cell lung cancer. Participants are assigned at random to either biportal surgery, which uses two incisions, or multiportal surgery, which uses several small ports. The study track…

Researchers are studying whether nutritional support helps people with advanced lung cancer maintain their weight, strength, and quality of life during chemotherapy. The trial enrolls 100 adults with high nutritional risk. Participants receive dietary advice or a structured nutri…

This study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…

This study tests a flexible palliative care program for people with advanced heart failure or certain cancers. The program adds more team members—like a social worker or nurse—as symptoms get worse. The goal is to improve quality of life and match care to each person's changing n…

Researchers are testing whether a home-based prehabilitation program can help older adults with non-small cell lung cancer prepare for surgery. The program combines aerobic exercise, breathing muscle training, functional and chest expansion exercises, nutrition guidance, and smok…

Researchers at the University of New Mexico collect ascites fluid, the liquid that builds up in the abdomen, from women undergoing surgery for ovarian cancer. They study this fluid and tumor tissue in the lab to learn how the tumor environment helps cancer spread within the perit…

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other organs but not yet to the brain. Researchers will analyze these samples for tumor DNA that might predict when the cancer…

This study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…

This study is for people with metastatic breast cancer, including estrogen receptor-positive and triple-negative types. It uses biomarkers from tumors and blood to guide treatment choices, comparing how long the cancer stays controlled on the new therapy versus the previous one. …

This study observes adults with advanced thyroid cancer who are receiving standard treatments in real-world settings, not in clinical trials. Researchers aim to understand barriers to accessing care and how well patients tolerate and respond to available medications. About 459 pa…

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

This study interviews cancer care providers, patients, and caregivers to learn their thoughts and feelings about receiving hospital-level care at home. The goal is to understand what people know and believe about home hospital care, so that future programs can be designed to bett…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

Researchers are investigating whether metabolic markers measured by PET/CT scans and tumor tissue tests can predict how well early-stage non-small cell lung cancer responds to immunotherapy given before surgery. Thirty patients with stage IB to IIIA NSCLC that lacks EGFR and ALK …

This study tests a decision-making support program based on restorative justice principles, designed specifically for Black adults who are at high risk for lung cancer. The goal is to see if this approach increases understanding, trust, and willingness to get screened. Forty-five…

This study is a registry that will follow 600 people with early-stage lung cancer who undergo a surgery called segmentectomy. Participants will fill out questionnaires about their health before surgery, shortly after, and six months later. The goal is to measure how long people l…

Researchers are studying whether a next-generation radiation delivery system can run a complete treatment workflow while patients hold their breath. The trial enrolls about 20 adults with tumors in the chest or upper abdomen who are already scheduled for stereotactic body radiati…

This study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…

This study aims to learn more about diseases that affect the salivary glands, which produce saliva. Researchers will collect medical data, blood, saliva, and tissue samples from people with these conditions, their relatives, and healthy volunteers. The goal is to better understan…

Researchers are exploring whether an experimental compound called BPR001-615 can reduce the growth of colorectal cancer cells taken directly from patients during surgery. The study also measures levels of a protein called BiP in blood and tumor tissue to see whether it could serv…

Researchers are studying whether a blood test that looks for tiny traces of cancer DNA can identify early-stage lung cancer patients who are unlikely to need extra treatment after surgery. The trial enrolls adults with stage IB to IIIA non-small cell lung cancer who have had comp…

This study collects biological samples—like blood, skin biopsies, and swabs—from people with or at risk for skin diseases, as well as healthy volunteers. Researchers will use these samples to study the causes of skin conditions and explore potential treatments. Up to 700 particip…

This study looks at how chemoradiation for locally advanced lung cancer affects the heart. Researchers will track 100 patients using heart tests, blood samples, and questionnaires. The goal is to see if tailoring treatment based on individual risk can reduce heart problems.

This study collects blood samples from 1,000 men with prostate cancer to look for genetic differences that might explain why some cancers stop responding to hormone therapy. Participants give blood at clinic visits, and researchers analyze DNA and other genetic material. No treat…

This study collects blood, bone marrow, and tissue samples from people with HIV, KSHV, or certain cancers to help researchers learn more about these diseases. Participants must be 18 or older and may have HIV, KSHV, or related conditions. No treatment is given; the goal is to gat…

This study looks at whether a simple blood test can help doctors decide if rectal cancer patients can avoid surgery and keep their rectum. Researchers will measure tiny bits of tumor DNA in the blood (ctDNA) before, during, and after standard treatment. The goal is to see if chan…

This study follows people with a rare genetic condition called DICER1 syndrome, which raises the risk of certain childhood cancers like pleuropulmonary blastoma. Researchers will collect medical histories, genetic samples, and tissue from up to 1,500 participants and their relati…

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study looks at whether genetic information from tumors can help doctors choose better treatments for pancreatic cancer. About 200 adults with early or locally advanced pancreatic cancer will receive standard chemotherapy and provide blood, tissue, and fluid samples for genet…

This study is building an AI tool called ACTIVATE that scans electronic health records to find cancer patients who may be eligible for clinical trials. Researchers will test whether sending alerts to doctors increases the number of patients starting trials. The goal is to make it…

This study looks at a rare inherited condition called Birt-Hogg-Dube (BHD) syndrome, which raises the risk of kidney cancer. Researchers will collect blood, saliva, and tissue samples from up to 950 participants to find the genes involved and understand how kidney tumors grow. Th…

This study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …

This study collects tissue samples and health information from 2000 adults with certain lung and thymic cancers. Researchers aim to better understand these diseases, which could lead to new diagnostic tools and treatments. Participants provide blood, tumor samples, and imaging da…

This study is for Black adults newly diagnosed with gastrointestinal cancer. It focuses on ensuring patients receive proper biomarker testing and evidence-based care, helping them find and join clinical trials if they choose, and providing easy-to-understand information about the…

This study is testing a new algorithm that uses a liquid biopsy (a simple blood test) to find HRR gene mutations in patients with metastatic prostate cancer. It is for patients whose tumor tissue is not available or is inadequate for standard testing. The goal is to see if this m…

Surgeons use imaging-guided techniques to locate breast tumors they cannot feel, aiming to remove the cancer completely while sparing healthy tissue. This large observational study compares several methods, including wire-guided localization, intraoperative ultrasound, magnetic s…

This study is a disease registry that will follow about 700 people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. Researchers will collect information on patient characteristics, treatments, and outcomes over time to better un…

This study looks at whether artificial intelligence (AI) can help radiologists find prostate cancer on MRI scans. About 150 men aged 55-80 who are scheduled for a prostate biopsy will take part. The AI software will be compared to radiologists reading the scans alone. The goal is…

This study is testing a new approach to personalize cancer treatment for people with colorectal or pancreatic cancer. Researchers will take a small sample of a patient's tumor, grow it in the lab, and test different drugs on it to see which one works best. The goal is to see if t…

This study looks at whether getting immunotherapy infusions in the morning versus the afternoon changes outcomes for people with advanced lung cancer or head and neck cancer. About 238 participants will be randomly assigned to morning or afternoon infusions. Researchers will trac…

This study looks at how the timing of a blood test that detects tumor DNA (ctDNA) affects understanding of prognosis and treatment choices in people with advanced HR+/HER2- breast cancer. Researchers will follow 400 participants to see how ctDNA levels and gene mutations relate t…

This study will test if measuring hand grip strength during clinic visits is practical and useful for adults with pancreatic cancer. Fifty participants will squeeze a handheld device and fill out well-being questionnaires alongside their regular care. Researchers want to see if c…

Researchers at University Hospital, Strasbourg, are developing 3D tumor models grown from patient tissue to study kidney, bladder, and prostate cancers. The study collects tumor samples and a small blood sample from about 100 adults with these cancers. Scientists use the blood to…

This study aims to learn more about oropharyngeal carcinoma, a type of throat cancer that can be linked to HPV. Researchers will collect blood samples from 1,000 patients before treatment and at six follow-up visits, and also gather tumor tissue when available. The goal is to bet…

This study looks at whether removing only a few key lymph nodes (sentinel node biopsy) is better than removing no nodes at all in women with early-stage endometrial cancer. The goal is to see if this approach helps women return to normal activities faster and does not increase th…

This study tests a communication tool called TrialTalk™ in cancer clinics. The goal is to see if it helps doctors and patients talk more clearly about treatment options. About 30 patients and their doctors will fill out questionnaires before and after a regular visit. The study f…

This study is testing an educational program designed to help racial and ethnic minority cancer patients make informed decisions about joining clinical trials. The program involves watching short videos and talking with a patient navigator. Researchers will measure changes in pat…

This study tests whether a newer, MRI-guided radiation method (MRgART) is gentler on the heart than standard radiation (LINAC) for people with lung, esophageal, or other chest cancers. About 60 adults will receive radiation and have their heart function checked via MRI and blood …

Researchers are testing whether breast cancer patients who give consent digitally can reliably report complications after surgery using questionnaires. The study includes 50 women with early invasive breast cancer who are having breast-conserving surgery and a sentinel lymph node…

This study reviews medical records from 600 lung cancer patients who had surgery between 2004 and 2019. The goal is to see if the use of robotic surgery has led to more atypical segmentectomies (removing part of a lung lobe). Researchers want to understand how robotic methods com…

This study looks at how well different labs agree when testing for a protein called FRa in stored tumor samples from women with ovarian cancer. About 1,000 women's archived tissue will be tested, but no new treatments or visits are needed. The goal is to improve consistency of FR…

Researchers are studying whether blood and tissue samples can show when metastatic breast cancer stops responding to standard first-line treatment with an aromatase inhibitor and a CDK4/6 inhibitor. The study enrolls women with ER-positive, HER2-negative metastatic breast cancer …

Some cancer drugs cause rare but serious heart and metabolic problems. This study follows 5,000 cancer patients across several French hospitals who receive a dedicated heart checkup and ongoing follow-up through cardio-oncology programs. Researchers track how many patients benefi…

Researchers at a single center are observing about 1,000 patients with hepatocellular carcinoma who receive systemic therapies. The study tracks overall survival, progression-free survival, and tumor response using standard imaging criteria. It also checks whether hepatitis C dru…

Cell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…

Researchers are observing people with small liver cancer, cirrhosis, and an overactive spleen who undergo laparoscopic liver surgery combined with spleen removal. The study enrolls 30 adults with low platelet counts and follows them for two years after surgery. It tracks changes …